Overall Status

Terminated (2)

Recruiting (1)

Sign in for free

Phase

phase 1 (2)

phase 1/phase 2 (1)

Sponsor

Dicerna Pharmaceuticals, Inc. (1)

Indapta Therapeutics, INC. (1)

Karyopharm Therapeutics Inc (1)

Collaborator

Study Documents

Intervention Type

drug (3)

Funder Type

Industry (3)

Study Type

Interventional (3)

NHL

Showing NaN - NaN of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

NHL, Multiple Myeloma, Blood Cancer Trial in Minneapolis, Houston, Fairfax (IDP-023, Rituximab, Daratumumab)

Recruiting

NHL
+6 more

IDP-023
+6 more

Minneapolis, Minnesota
+2 more

Nov 7, 2023

Solid Tumors, NHL Trial in Canada, United States (KPT-9274, Niacin ER, Nivolumab)

Terminated

Solid Tumors
NHL

KPT-9274
+2 more

Los Angeles, California
+7 more

Jan 18, 2023

Solid Tumors, Multiple Myeloma, Non-Hodgkins Lymphoma Trial in United States (DCR-MYC)

Terminated

Solid Tumors
+5 more

DCR-MYC

Stanford, California
+5 more

Dec 13, 2017